Edwards Lifesciences Stock: The Barriers to Entry

When it comes to barriers to entry associated with mid-cap and the smaller of the large-cap stocks, few if any companies enjoy the competitive advantage possessed by Edwards Lifesciences. The company operates in the incredibly regulated field of aortic valve replacements and surgical heart valve therapy. 

One of its well-established and fast-growing products is the Transcatheter Aortic Valve Replacement (TAVR), and the companies’ Sapien 3 valves exhibit the lowest rate of death, stroke, or rehospitalization among its users. The Sapien 3 is a valve made out of cow tissue that is attached to a balloon-expandable, cobalt-chromium frame for support. 

What I find noteworthy (from an investment point of view) about the Sapien 3 … Read the rest of this article!

T. Rowe Price: One Of Those Ignored Blue-Chip Stocks


I was thinking about the GT Advanced Technologies announcement earlier this week when my mind drifted to some of the truly excellent businesses that have been able to deliver growth this past decade without adding debt to make investments or repurchase stock. That’s not necessarily a bad thing—if your company can take on debt at 1%, 2%, 3%, or 4% interest rates, and if the stock is trading at a price that is less than what it would fairly be worth, it can make long-term shareholders richer than they’d otherwise be if you didn’t do the buyback.

However, I’ve always had a soft spot for companies that are able to deliver high long-term … Read the rest of this article!